AGENDA
Utah Department of Health
Pharmacy and Therapeutics Committee
Thursday, February 15, 2018
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 125
Persons who wish to address the P&T Committee may contact Bryan S. Larson at (bslarson@utah.gov) prior to the meeting, or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints.
1) Call to order - Clinton Sheffield, MD, Chair
a) Announce Quorum
2) Welcome and Introductions - Clinton Sheffield, MD, Chair
a) Review and Approval of Minutes
b) Housekeeping
i) Annual Training - Tony Patterson, Assistant Attorney General
3) DUR Board Update - Robyn Seely, PharmD
4) February Review
a) Nasal Corticosteroids - Valerie Gonzales, PharmD
i) Beclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone Furoate, Fluticasone Propionate,
Mometasone, Triamcinolone
b) Public Comment
c) Other States Report - Bryan S. Larson, PharmD
d) Committee Discussion/Questions
e) Committee Action
5) Next Meeting March 15, 2018, Extrapyramidal Disorder/Movement Disorder Agents
6) Adjourned - Clinton Sheffield, MD, Chair
The foundation documents used for most reviews are prepared by the University of Utah, College of Pharmacy, and are posted on the P&T Committee website after the meeting. Manufacturers wishing to submit any additional materials they would like reviewed as part of the process to:
Dr. Joanne LaFleur
College of Pharmacy
30 South 2000 East
SLC, UT 84112-5820
All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible), unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.
Tentative Upcoming Pharmacy & Therapeutics Committee Schedule
Month Topic Agents
15 Mar 2018 Extrapyramidal Disorder/ Movement Disorder Agents Benztropine, Deutetrabenazine, Tetrabenazine, Trihexyphenidyl, Valbenazine
19 Apr 2018 Nonsteroidal AntiInflammatory Drugs
(NSAIDs) Diclofenac, Etodolac, Fenoprofen, Ibuprofen, Indomethacin, Ketoprofen, Ketorolac, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Piroxicam, Sulindac, Tolmetin
17 May 2018 Proton Pump Inhibitors (PPIs) Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole
21 Jun 2018 Low Molecular Weight Heparins (LMWH) Dalteparin, Enoxaparin, Fondaparinux, Tinzaparin
19 Jul 2018 TBD TBD
16 Aug 2018 TBD TBD
20 Sep 2018 TBD TBD
Please note: all topics are tentative and subject to change.
Notice of Special Accommodations (ADA)
In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Bryan Larson at 801-538-6149.